Abstract
Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p=0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Cell Hypoxia
-
Female
-
Humans
-
Imidazoles / adverse effects
-
Imidazoles / therapeutic use*
-
Intraoperative Period
-
Male
-
Middle Aged
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / radiotherapy*
-
Pancreatic Neoplasms / surgery
-
Radiation-Sensitizing Agents / adverse effects
-
Radiation-Sensitizing Agents / therapeutic use*
-
Survival Rate
Substances
-
Imidazoles
-
Radiation-Sensitizing Agents
-
doranidazole